Alumis Inc.
ALMS
Classement en actions
#9970
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Prix de l'action
$6.69
Capitalisation boursière
$865.92M
Changement (1 jour)
5.52%
Changement (1 an)
194.71%
Pays
US
Échange Alumis Inc. (ALMS)
Catégorie
Healthcare
Nombre d'actions en circulation pour Alumis Inc. (ALMS)
Nombre d'actions en circulation au March 2025: 100.68M
Selon les derniers rapports financiers et le cours de l'action de Alumis Inc., le nombre actuel d'actions en circulation est de 100.68M. À la fin de December 2023, l'entreprise avait 70.25M actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Alumis Inc. (ALMS) de 2021 à 2026
Actions en circulation à la fin de chaque année
| Année | Actions en circulation | Changez |
|---|---|---|
| 2026 (TTM) | 100.68M | 1.39% |
| 2024 | 99.30M | 41.35% |
| 2023 | 70.25M | 243.63% |
| 2022 | 20.44M | 0.00% |
| 2021 | 20.44M | 0.00% |
Actions en circulation pour des entreprises similaires ou concurrentes
| Entreprise | Actions en circulation | Différence | Pays |
|---|---|---|---|
| 253.90M | 152.18% |
US
|
|
| 396.00M | 293.32% |
US
|
|
| 478.91M | 375.68% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -38.23% |
NL
|
